Trial reportArtificial organs2025
Dorsal Genital Nerve Stimulation as an Adjunctive Therapy to Control Neurogenic Detrusor Overactivity After Spinal Cord Injury.
Trial report in Artificial organs, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundSpinal cord injury (SCI) causes impairment to bladder function. As current management strategies are not fully effective, there remains a need for alternative or adjunctive management options. Dorsal genital nerve stimulation (DGNS) has been shown to effectively inhibit unwanted bladder contractions in people with SCI. However, the acceptance and beneficial effects of home-based DGNS have not yet been proven.
methodsThis pilot trial investigated the feasibility and user acceptance of a novel DGNS device, UCon (InnoCon Medical, Denmark) when used at home by people with SCI for 8 weeks. Cystometry with and without DGNS was performed before and after the intervention. Outcome measures included 3-day bladder diaries (3DBD), quality of life, and user acceptance questionnaires, and a semi-structured interview.
resultsTen people with chronic SCI and neurogenic detrusor overactivity participated in the trial and used the device at home for 8 weeks. When tested at baseline, DGNS significantly increased maximum cystometric capacity (MCC) from 276 (125) to 394 (147) ml with DGNS applied (p < 0.001). After the 8-week intervention, no change in MCC without stimulation was noted. No change in bladder capacity or incontinence episodes was found from 3DBDs and quality of life was not significantly changed. User acceptance of the device was high, with some issues noted, particularly around device disconnection.
conclusionsOur results support the application of DGNS to increase bladder capacity after SCI, and user acceptance of home-based DGNS was high. This therapy should be studied in a larger subject group to prove the effectiveness of home-based DGNS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.